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ABSTRACT
Bronchial hyperresponsiveness (BHR) is a characteristic
feature of bronchial asthma, yet its precise mechanism
remains obscure. Human studies have demonstrated
that T helper 2 cytokines, including interleukin (IL)-4
and IL-5, are involved in the development of airway
inflammation and BHR. In the present study, we exam-
ined the role of IL-5 in the onset and aggravation of
bronchial responsiveness to acetylcholine in two strains
of IL-5 transgenic (Tg) mice, derived from the
C3H/HeN and BALB/c strains. Three inhalations of
antigen (ovalbumin) caused an increase in the number
of eosinophils in bronchoalveolar lavage fluid (BALF)
and a significant elevation in serum IgE in wild-type
mice. In contrast with wild-type animals, systemic over-
production of IL-5 resulted in massive airway
eosinophilia, especially around the peribronchi and
perivascular regions of the tissues, after repeated
antigen provocation. In C3H/HeN background IL-5 Tg
mice, repeated antigen provocation did not induce
BHR similar to that of wild-type mice. In contrast,
antigen-induced BHR was observed in BALB/c-
background mice, but there were no significant differ-
ences between the magnitude of BHR in wild-type 
and IL-5 Tg mice. Furthermore, antigen-induced IL-5
production in BALF was detected in both C3H/HeN
and BALB/c mice and was elevated to a similar degree
in both wild-type and IL-5 Tg mice. These findings
suggest that systemic overproduction of IL-5 or airway
eosinophilia is not, by itself, important in the develop-
ment or aggravation of antigen-induced BHR in mice.
Key words: bronchial hyperresponsiveness, eosino-
phils, interleukin-5, mice.
INTRODUCTION
Bronchial hyperresponsiveness (BHR) is a characteristic
feature of most asthmatics and it correlates with the
severity of the disease.1 Recent investigations have
demonstrated that eosinophilic inflammation of the air-
way is another important feature of asthma2 and airway
inflammation is thought to be a causative factor in the
development of BHR. Among the candidate factors,
which include cytokines and inflammatory mediators,
particular interest has been paid to interleukin (IL)-5
because IL-5 is a crucial factor in the control of eosino-
phil functions, such as differentiation,3 prolongation of
survival,4 activation and degranulation.5 Moreover,
eosinophil-derived mediators appear to play an impor-
tant role in the development of BHR.6–8
Recent studies have investigated the role of IL-5 in
the development of BHR using monoclonal antibodies
(mAbs),9–14 transgenic (Tg) mice15–17 and gene-disrupted
mice;18 however, the correlation between airway eosin-
ophilia and airway function remains controversial.12,19,20
Furthermore, evidence for a role of IL-5 in the develop-
ment of BHR is conflicting.9,10,14,15,17,18
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We have recently demonstrated that repeated antigen
inhalation leads to an increase in the level of T helper (Th)
2 cytokines, including IL-4 and IL-5,21 in the number of
inflammatory cells, mainly eosinophils, in bronchoalveo-
lar lavage fluid (BALF)9,10,21,22 and in BHR to acetylcholine
(ACh),9,10,21–23 with a significant elevation in serum antigen-
specific IgE in sensitized BALB/c mice.23 Furthermore, the
development of antigen-induced BHR is T lymphocyte
dependent22 and mast cell dependent,23 suggesting that
a Th2 pattern of cytokine production and IgE-mediated
responses may be associated with the development of
these allergic responses. We have also investigated the
role of IL-5 in the onset of airway eosinophilia and BHR
using a mouse model.9,10,21,22 However, anti-IL-5 mAb9,10
and IL-5 soluble receptor α chain,21 administered during
antigen inhalation, failed to inhibit BHR in sensitized
mice. In contrast, we examined the role of IL-5 receptor α
chain using mice that are genetically deficient in the
receptor α chain.24 As a result, the IL-5 receptor α chain
and IL-5 showed a crucial role in the onset of airway
eosinophilia and BHR,24 suggesting that IL-5 is involved
in the development of allergen-induced BHR, although it
appears to be difficult to regulate its function during the
effector phase.
Strategies of gene manipulation, such as ‘knockout’
or ‘transgenic’, are important methods to understand the
roles of certain molecules, especially in mice. However,
recent studies have reported that the genetic back-
ground may directly influence the interpretation of the
effect of gene disruption in some cases.25–27 Regarding
bronchial responsiveness to stimuli, several studies have
reported on different strains of inbred mice with differ-
ences in airway responsiveness.28–30 Levitt and Mitzner28,29
initially reported strain differences in responsiveness. Of
nine common inbred mice, A/J and AKR/J mice showed
the greatest responsiveness to ACh injected exoge-
neously and BALB/c showed a moderate responsiveness,
whereas C57BL/6, SJL/J and C3H/HeJ mice exhibited
the least responsiveness.28 In addition to airway respon-
siveness, it has been reported, especially in mice, that
the production of IgE also depends on the genetic back-
ground.31,32
To date, however, no studies have investigated the role
of IL-5 using different strains of IL-5 Tg mice in the same
experimental protocol. Thus, the purpose of present study
was to clarify the role of IL-5 in the development of
aeroallergen-induced airway inflammation and BHR
using two different strain backgrounds of IL-5 Tg mice,
namely C3H/HeN and BALB/c.
METHODS
Animals
Seven-week-old male IL-5 Tg mice (derived from the
C3H/HeN and BALB/c strains) weighing 25–30 g were
prepared and maintained as described previously.33
Age-matched male animals were used as wild-type con-
trols. All animals were housed in plastic cages in an air-
conditioned room at 22 ± 1°C with a relative humidity 
of 60 ± 1%, were fed a standard laboratory diet and
were given water ad libitum. Experiments were performed 
following the 1987guidelines for the care and use of
experimental animals of the Japanese Association for
Laboratory Animals Science.
Agents
Ovalbumin (OA; Seikagaku Kogyo, Tokyo, Japan),
acetylcholine chloride (ACh; Nacalai Tesque, Kyoto,
Japan), bovine serum albumin (BSA; Seikagaku Kogyo),
Turk solution (Wako Pure Chemical Industries, Osaka,
Japan), pancronium bromide (Sigma Chemical Co., 
St Louis, MO, USA), pentobarbital sodium (Abbott Lab-
oratories, Chicago, IL, USA), disodium ethylendi-
aminetetraacetic acid (EDTA-2Na; Nacalai Tesque),
Diff-Quick solution (International Reagent Corp., Kobe,
Japan), monoclonal antimouse IgE antibody (LO-ME-3;
Serotek, Oxford, UK), monoclonal antidinitrophenol IgE
antibody (anti-DNP IgE, Clone SPE-7; Sigma Chemical
Co.), peroxidase-conjugated streptavidin (Dakopatts a/s,
Glostrup, Denmark) and peroxidase-labeled antimouse
IgE (Nordic Immunology, Tilburg, Netherlands) were pur-
chased commercially.
Sensitization and antigen challenge
Mice were actively sensitized by intraperitoneal injections
of 50 µg OA with 1 mg alum on days 0 and 12. Starting
on day 22, mice were exposed to OA (1% w/v diluted in
sterile saline) for 30 min three times every 4th day accord-
ing to a previously reported method.21 Non-sensitized
animals received 1 mg alum and were exposed to saline
in a similar manner. In a previous study, we compared the
effect of sensitization on airway function and airway
inflammation in saline-exposed animals; there were no
significant differences in these parameters.24 Thus, we
chose two groups for the present study. The aerosol (par-
ticle size 2.0–6.0 µm) was generated by a nebulizer
(ultrasonic nebulizer TUR-3200; Nihon Koden, Tokyo,
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Japan) driven by filling a perspex cylinder chamber
(5.5 cm diameter, 12 cm height) with a nebulized solution.
Measurement of immunoglobulins
Immediately before the last antigen challenge, blood was
collected and the serum was obtained by centrifugation
and was stored at –80°C. Antigen-specific IgE and total
IgE in mouse serum were measured using ELISA, as
described previously.23 Briefly, serum OA-specific IgE was
measured by coating monoclonal rat antimouse IgE anti-
body (LO-ME-3) at a concentration of 5 µg/mL. After
blocking with 1% BSA, serum dilutions were incubated 
for 1 h followed by biotinylated-OA and peroxidase-
conjugated streptavidin. Sequentially diluted monoclonal
anti-OA IgE was used as a standard. Serum total IgE was
measured by coating monoclonal rat antimouse IgE anti-
body (LO-ME-3) at a concentration of 5 µg/mL. After
blocking with 1% BSA, serum dilutions were incubated 
for 1 h followed by peroxidase-labeled antimouse IgE.
Sequentially diluted monoclonal anti-DNP IgE antibody
(SPE-7) was used as a standard. Optical densities of the
enzymatic reactions were measured using an automatic
ELISA plate reader (Titertek Multiscan MCC/340; Lab
Systems Oy, Helsinki, Finland) at 450 nm (reference
wavelength 690 nm). The detection limit was 10 ng/mL.
Bronchoalveolar lavage study
To evaluate airway inflammation, we studied the accumu-
lation of inflammatory cells in bronchoalveolar lavage
fluid (BALF). Experiments were performed according to
previously described methods.9,21 Briefly, 24 h after the
last inhalation of antigen (30 days after the first immu-
nization), test animals were killed by intraperitoneal
injection of sodium pentobarbitone (100 mg/kg). The
trachea was cannulated and the air lumen was washed
four times with 1 mL calcium- and magnesium-free 
phosphate-buffered saline (PBS) containing 0.1% BSA
and 0.05 mmol/L EDTA-2Na. The BALF obtained from
each animal was pooled in a plastic tube, cooled in ice
and centrifuged (150 g) at 4°C for 10 min. Cell pellets
were resuspended in the same buffer (1 mL) and the pro-
cedure was repeated three times (total volume 3 mL;
recovery > 85%). The number of nucleated cells in BALF
stained with Turk solution was counted in a Bürker
chamber and a differential count under a microscope
(× 500) was made on a smear of at least 300 cells pre-
pared with a cytocentrifuge (Cytospin II, Shandon,
England) and stained with Diff-Quick solution (based on
standard morphologic criteria). The amount of IL-5 in the
sera or BALF was measured using ELISA (Endogen Inc.,
Cambridge, MA, USA).
Measurement of airway function
Measurement of airway responsiveness to ACh was per-
formed according to methods described previously with
some modifications.23 Briefly, in order to measure airway
responsiveness to ACh, mice were anesthetized with
sodium pentobarbitone (80 mg/kg, i.p.) and the jugular
vein was cannulated for intravenous injection of ACh.
Mice were injected with pancronium bromide (0.1 mg/kg,
i.v.) to suppress spontaneous respiration and animals
were ventilated with a rodent ventilator (New England
Medical Instruments, Medway, MA, USA) with air supple-
mented with oxygen at 60 strokes/min, with a stroke
volume of 0.6 mL/animal. Bronchoconstriction was mea-
sured according to the overflow method described by
Konzett and Rössler,34 using a bronchospasm transducer
(Ugo Basile 7020, Milano, Italy) connected to the tra-
cheal cannula. To measure the bronchial responsiveness
to ACh, changes in the respiratory overflow volume were
measured using increasing doses of ACh. The increase 
in respiratory overflow volume provoked by ACh is repre-
sented as a percentage of the maximal overflow 
volume (100%) obtained by clamping the tracheal
cannula. Area under the curve (AUC) was calculated
from the data of the dose–response curve for ACh (range
125–2000 µg/kg), as described previously.23
Histologic study
Mice were killed 24 h after the third antigen inhalation
and whole lungs were distended by instillation of 10%
buffered formalin via the trachea, removed and immersed
in the same fixative with the trachea clamped for 24 h.
Tissues were sliced and embedded in paraffin and 6 µm
sections were stained with hematoxylin and eosin for light
microscopic examination.
Statistical analyses
Values are presented as the mean±SEM. Statistical sig-
nificance between saline- and OA-inhaled animals or
between wild-type and Tg animals was estimated using
the two-tailed Student’s t-test or the Aspin–Welch test.
P < 0.05 was considered statistically significant.
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RESULTS
Effect of IL-5 transgene on BAL leukocyte
influx and local IL-5 production in the airways
To test whether systemic IL-5 overproduction influences
BAL and airway leukocyte accumulation and also local 
IL-5 production in the airways, IL-5 Tg mice were immu-
nized with OA and exposed to OA aerosol three times
and compared with age- and sex-matched wild-type
mice. On day 31, 24 h after the last antigen inhalation,
BAL was performed.
In IL-5 Tg mice, repeated antigen provocation caused
striking BAL eosinophilia and also marked increases in
the number of total leukocytes and lymphocytes com-
pared with saline-injected control groups (Fig. 1). In
contrast with each IL-5 Tg mouse, analysis of BAL cells 
of OA-exposed wild-type mice revealed a selective
increase in the number of eosinophils. The number of
total leukocytes and lymphocytes also increased or
tended to increase.
Histologic analysis of lungs, taken from saline-injected
wild-type and IL-5 Tg mice, showed normal lung histo-
logy with no inflammation and (Fig. 2a,c,e,g). In
contrast, histologic sections of lung tissue from OA-
inhaled wild-type mice exhibited pulmonary eosinophilic
inflammation. Infiltrating eosinophils were mainly seen in
the peribronchial and perivascular regions of the lungs
(Fig. 2b,f). Furthermore, after aeroantigen challenge of
IL-5 Tg mice, a marked increase in the number of
eosinophils was observed, especially in the peribronchial
and perivascular regions (Fig. 2d,h). There were no 
significant differences in histologic analyses among the
OA-inhaled groups, except for the increased number of
eosinophils and lymphocytes in IL-5 Tg animals.
The amount of IL-5 in BALF after antigen challenge is
shown in Fig. 3. In wild-type mice, the level of IL-5 in
BALF was significantly elevated 24 h after aeroantigen
challenge, although the amount of IL-5 in BALF from
C3H/HeN mice was less than that of BALB/c mice.
Furthermore, there were no significant differences in IL-5
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Fig. 1 Antigen-induced leukocyte accumulation in bronchoalveolar lavage fluid (BALF) obtained from interleukin (IL)-5 transgenic
(Tg) mice and wild-type mice from either a C3H/HeN background (a–c) or a BALB/c background (d–f). (a,d) Total cells, 
(b,e) eosinophils, (c,f) lymphocytes. Each column represents the mean±SEM of six mice. *P < 0.05, **P < 0.01 and ***P < 0.001
compared with saline inhalation (). †P < 0.05 compared with wild type. (), ovalbumin inhalation.
production after antigen challenge between wild-type
and IL-5 Tg mice (Fig. 3).
Effect of IL-5 transgene on serum IgE levels
To study the role of the IL-5 transgene in antigen-induced
IgE production, total serum IgE and antigen-specific IgE
levels were measured. Serum was obtained from mice on
day 30, immediately before the last antigen provocation.
Sensitization and repeated antigen provocation
caused significant increases in the level of total serum IgE
and antigen-specific IgE when compared with the saline-
injected groups; however, there were no significant
differences between wild-type and IL-5 Tg mice (Fig. 4).
In contrast with the OA-inhaled groups, total IgE did not
increase and also OA-specific IgE remained below the
detection limit (< 10 ng/mL) in the serum of saline-
injected groups.
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Fig. 2 Histologic analysis of
lung sections from wild-type
(a,b,e,f) and interleukin (IL)-5
transgenic (Tg) (c,d,g,h) mice.
(a–d) C3H/HeN mice, (e–h)
BALB/c mice. (a,c,e,g) Normal
features in the control group
challenged with saline (original
magnification x 50). (b,f) After
immunization and repeated
challenge with ovalbumin in wild-
type mice, inflammatory infil-
trates were present around the
peribronchial and perivascular
regions (original magnification
x 50). (d,h) After immunization
and repeated antigen provoca-
tion, massive eosinophilia and
mononuclear leukocytes were
also present around the peri-
bronchial and perivascular
regions in IL-5 Tg mice (original
magnification x 50).
Effect of the IL-5 transgene on airway 
responsiveness to ACh
To clarify the effect of systemic IL-5 overproduction on
airway function, airway responsiveness to ACh was exam-
ined. Figure 5 shows the AUC of the dose–response to
ACh in all groups.
In C3H/HeN mice, BHR to ACh was not observed in
either wild-type or IL-5 Tg mice, even after repeated
antigen challenge. In contrast, repeated aeroantigen
provocation caused a significant increase in the airway
responsiveness to ACh in both wild-type and IL-5 Tg mice
of the BALB/c strain, although there were no significant
differences between wild-type and IL-5 Tg mice.
DISCUSSION
In the present study, we demonstrated that repeated
antigen inhalation caused a marked increase in the
number of eosinophils in BALF and in the airways of sen-
sitized IL-5 Tg mice. Furthermore, antigen-induced IL-5
production in BALF was observed in both strains, but
showed a similar level in wild-type and IL-5 Tg mice. In
addition, antigen-induced BHR was observed in BALB/c
mice, whereas the BHR did not develop in C3H/HeN
mice, even in IL-5 Tg mice. Thus, the present findings
suggest that systemic overproduction of IL-5 or airway
eosinophilia is not, by itself, a causative factor in the
development or aggravation of BHR.
Clinical studies have demonstrated that the number of
CD4+ T cells and eosinophils often correlates with
disease severity.35 As described above, it has been
reported that IL-5 regulates eosinopoiesis,3 eosinophil
survival3,4 and activation.5 In both IL-5 Tg mice strains,
repeated antigen challenge resulted in massive airway
eosinophilia, compared with wild-type mice, whereas
antigen-induced IL-5 production in BALF was observed in
both strains and showed a similar level in wild-type and
IL-5 Tg mice, suggesting that IL-5 plays an important
role in eosinophil differentiation rather than as chemo-
attractant factor into the airways. These findings are 
in agreement with reports of differentiation of in vitro
eosinophils by IL-53 and suppression of in vivo eosin-
ophilia by mAb to IL-5 in mice.9,10,12–14 Thus, cytologic
and histologic examination of antigen-inhaled IL-5 Tg
mice revealed a crucial role for IL-5 in the induction of
airway eosinophilia.
Second, we examined whether the IL-5 transgene influ-
ences IgE production provoked by repeated antigen
provocation in sensitized mice. It has been reported that
IL-5 potentiates the IL-4-induced IgE response in vitro;36
however, the present findings showed no significant dif-
ferences in antigen-induced IgE production between
wild-type and IL-5 Tg mice. Thus, antigen-induced IgE
response in this model may not be influenced by IL-5.
The main question to be discussed in the present study
is whether systemic overproduction of IL-5 by itself
induces BHR and whether it augments or aggravates
antigen-induced BHR, which was observed in wild-type
mice. Antigen provocation caused an increase in the
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Fig. 3 Antigen-induced increases in interleukin (IL)-5 levels
in bronchoalveolar lavage fluid (BALF) obtained from wild-
type and IL-5 transgenic (Tg) mice with (a) a C3H/HeN 
or (b) BALB/c background. Each column represents the
mean±SEM of six mice. ND, not detected (< 5 pg/mL); OA,
ovalbumin.
number of eosinophils and lymphocytes around vessels
and bronchi in humans37 and, as shown here, in wild-type
and IL-5 Tg mice strains. The present findings show that
systemic overproduction of IL-5 caused an increase in the
number of eosinophils without either immunization or
antigen challenge in IL-5 Tg mice and that repeated
antigen challenge caused massive airway eosinophilia in
IL-5 Tg mice of both strains. In contrast with the role of 
IL-5 in airway eosinophilia, saline-injected IL-5 Tg mice
with slight airway eosinophilia did not exhibit BHR for
both strains. In addition, in OA-inhaled C3H/HeN-back-
ground mice, antigen challenge did not induce BHR,
even in IL-5 Tg mice, which revealed massive airway
eosinophilia. Furthermore, antigen-induced BHR was
observed in both BALB/c strains, but the exaggeration of
BHR was not observed in IL-5 Tg mice. These findings
suggest that neither systemic IL-5 overproduction nor
airway eosinophilia is, by itself, important for the develop-
ment or augmentation of BHR. These observations are in
agreement with recent clinical studies, in which adminis-
tration of a humanized blocking mAb to IL-5 did not
improve the airway function of asthmatics, whereas it
clearly decreased the number of eosinophils in sputum
and peripheral blood.38,39
In the present study, BHR was not observed after
aeroallergen challenge in either wild-type or IL-5 Tg
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Fig. 4 Antigen-induced increases in (a,c) antigen-specific IgE and (b,d) total IgE levels in sera obtained from wild-type and inter-
luekin (IL)-5 transgenic (Tg) mice with (a,b) a C3H/HeN or (c,d) BALB/c background. Each column represents the mean±SEM of six
mice. **P < 0.01, ***P < 0.001 compared with saline inhalation (). ND, not detected (< 10 ng/mL). (), ovalbumin inhalation.
C3H/HeN mice, whereas IgE production, IL-5 produc-
tion in BALF and airway eosinophilia were all detected. It
is unclear why BHR did not develop in this strain;
however, perhaps in this strain some factors that may
contribute to the development of BHR are defective or did
not work functionally. With regard to bronchial respon-
siveness to ACh, the degree was markedly lower than that
of BALB/c mice. Thus, further experiments will be needed
to clarify the mechanisms in C3H/HeN mice compared
with BALB/c mice.
In contrast, BHR was not augmented after aeroallergen
challenge even in IL-5 Tg BALB/c mice, whereas striking
airway eosinophilia was observed. The reason why the
aggravation of BHR was not detected in the IL-5 Tg mice
is unknown; however, some possibilities exist. The degree
of BHR observed in wild-type mice was already maximal;
thus, we could not observe exaggeration of BHR in IL-5
Tg mice. However, we recently established another
chronic asthma model in BALB/c mice. In this model,
mice were sensitized using an identical method and then
challenged with aeroallergen (1%) for 3 consecutive
weeks, instead of three times every 4th day. As a result,
the degree of BHR was stronger and more severe than
that observed in the present study (data not shown). The
other possibility is that infiltrated eosinophils are not fully
activated, although the number of eosinophils in BALF or
lung tissue was significantly enhanced in IL-5 Tg mice.
Thus, further experiments will be needed to clarify
whether eosinophils are activated.
Recently, the use of IL-5 transgenic animals in biologic
and pathologic studies has become a standard investi-
gative approach; however, the correlation between
airway eosinophilia and airway function remains contro-
versial.15–17 Lefort et al.15 have demonstrated that sys-
temic IL-5 production influences antigen-induced airway
eosinophilia, but not airway function, in CBA background
mice, which did not exhibit antigen-induced BHR even in
wild-type mice. In contrast, Lee et al.17 have reported that
a lung-specific IL-5 transgene could induce BHR without
immunization or antigen challenge. In addition, Iwamoto
and Takatsu16 investigated the role of IL-5 in antigen-
induced BHR using the same mice strains used in the
present study, suggesting IL-5 is an important factor in 
the onset of BHR. These conflicting findings, including 
the present observations, may be due to either lung-
specific effects, different protocols or strain gene back-
grounds.
In conclusion, the present study indicated that systemic
overproduction of IL-5 or airway eosinophilia is not, by
itself, required in the development and aggravation of
BHR.
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